WHAT: FDA Website on FDA standards for Abuse-Deterrent (AD) opioid formulations
WHY: To help drug makers expedite regulatory path to market as quickly as possible. FDA is taking a flexible, adaptive approach to the evaluation and labeling of potentially AD products.
- Targiniq ER
- Hysingla ER
- Xtampza ER
- Troxyca ER
NO immediate-release products with FDA-approved AD labeling c